Literature DB >> 8199563

T suppressor activated lymphocytes (CD8+/DR+) inhibit megakaryocyte progenitor cell differentiation in a case of acquired amegakaryocytic thrombocytopenic purpura.

F Benedetti1, D de Sabata, G Perona.   

Abstract

Acquired amegakaryocytic thrombocytopenic purpura (AATP) is a rare disease, characterized by isolated thrombocytopenia and the absence of megakaryocytes in bone marrow. Recent studies suggest that this syndrome is due to diverse etiologies. Humoral or cellular mediated suppression has been alternately demonstrated using an in vitro colony assay for megakaryocytic progenitor cells (colony forming units megakaryocyte, [CFU-meg]). We studied a patient affected by AATP, who was not responsive to conventional therapy, but did respond to antilymphocyte globulin. The immunological characterization of marrow lymphocytes showed a marked increase of T activated suppressor cells (CD8+/DR+). Low density bone marrow mononuclear nonadherent cells (MNAC) from the patient, either in aplastic phase or in remission phase, were plated in plasma clot either directly or after T cell depletion (T-dep MNACs). Co-cultures with normal marrow cells were performed using either T lymphocytes from a normal volunteer donor or patient T lymphocytes. In some experiments we added autologous serum instead of fetal calf serum (FCS). In standard conditions, we observed increased colony formation, which was more evident in remission phase and especially significant after T cell depletion. The T lymphocytes from patient marrow did not modify the number of CFU-meg when co-cultured with allogeneic cells. These results indicate that an immune-mediated mechanism could be responsible for this case of AATP, and that the T cell subset CD8+/DR+ is capable of exerting suppression on megakaryocyte differentiation. This suppressive effect seems restricted to patient cells, suggesting a specific auto-sensitization.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8199563     DOI: 10.1002/stem.5530120209

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  7 in total

Review 1.  Advances in immunopathogenesis of adult immune thrombocytopenia.

Authors:  Xinguang Liu; Yu Hou; Jun Peng
Journal:  Front Med       Date:  2013-11-21       Impact factor: 4.592

2.  Anti-CD20 Antibody is Effective in the Patient with Refractory Amegakaryocytic Thrombocytopenia, 25 Months Follow up.

Authors:  Mehrzad Mirzania; Sedigheh Khalili; Akbar Hasanpoor; Ahmad Reza Shamshiri
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2014

3.  Successful treatment of acquired amegakaryocytic thrombocytopenic purpura refractory to corticosteroids and intravenous immunoglobulin with antithymocyte globulin and cyclosporin.

Authors:  Pimjai Niparuck; Vichai Atichartakarn; Suporn Chuncharunee
Journal:  Int J Hematol       Date:  2008-07-15       Impact factor: 2.490

4.  Danazol: an effective option in acquired amegakaryocytic thrombocytopaenic purpura.

Authors:  E Mulroy; S Gleeson; S Chiruka
Journal:  Case Rep Hematol       Date:  2015-04-05

5.  Acquired Amegakaryocytic Thrombocytopenia in Adult-onset Still's Disease: Successful Combination Therapy with Tocilizumab and Cyclosporine.

Authors:  Takanori Ichikawa; Yasuhiro Shimojima; Toshiaki Otuki; Ken-Ichi Ueno; Dai Kishida; Yoshiki Sekijima
Journal:  Intern Med       Date:  2019-08-06       Impact factor: 1.271

6.  Acquired amegakaryocytic thrombocytopenia after durvalumab administration.

Authors:  Takahiro Suyama; Masao Hagihara; Naoto Kubota; Yoshiyuki Osamura; Yoko Shinka; Naoki Miyao
Journal:  J Clin Exp Hematop       Date:  2021-01-08

7.  Case Report: Successful Avatrombopag Treatment for Two Cases of Anti-PD-1 Antibody-Induced Acquired Amegakaryocytic Thrombocytopenia.

Authors:  Xiaofang Tu; Ali Xue; Suye Wu; Mengmeng Jin; Pu Zhao; Hao Zhang
Journal:  Front Pharmacol       Date:  2022-01-27       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.